Lapdap (chlorproguanil-dapsone) is an affordable and effective drug, but patients with
glucose-6-phosphate dehydrogenase (G6PD) A- deficiency are more susceptible to the haemolytic
effects of the dapsone component of Lapdap; therefore there is a need to evaluate the extent
to which the risks associated with the use of the drug in settings without G6PD screening
might outweigh the benefits to malaria treatment. The investigators will evaluate, in
operational settings, the safety and effectiveness of Lapdap and coartemether
(lumefantrine-artemether) for treatment of uncomplicated malaria in patients 6 months to 10
years of age.
Phase:
Phase 3
Details
Lead Sponsor:
London School of Hygiene and Tropical Medicine
Collaborators:
Medical Research Council National Malaria Control Programme, The Gambia